Differences

This shows you the differences between two versions of the page.

--- worked_example3 [2016/02/09 14:44] – fsalavert
+++ worked_example3 [2017/05/24 15:27] (current) – external edit 127.0.0.1
@@ Line 37: / Line 37: @@
-  * In this example we simulate the effect of treating cells with Erlotinib (FDA approved EGFR inhibitor for treatment of NSCLC EGFR mutant). We modify the target actions fixing: Agonist = 0.8 and Antagonist = 0.1 (mechanisms of action of Erlotinib on its targets).// Figure 1// shows how modify the expression of those genes.
+  * In this example we simulate the effect of treating cells with Erlotinib (FDA approved EGFR inhibitor for treatment of NSCLC EGFR mutant). We modify the target actions fixing: Agonist = 0.8 and Antagonist = 0.1 (mechanisms of action of Erlotinib on its targets).// Figure 1// shows how modify the expression of those genes using the setting panel.
+  *  To open the settings panel click on the //Settings// button located at the top right corner.
+ {{ :ex3settings.png?400 |}}
 {{ :gse57156_3.png?600 |}}
@@ Line 87: / Line 91: @@
 **Figure 9:** PathAct report. **A:** list of perturbed genes and final value of activation. **B:** ranked circuits by log fold change (base 10). Note how PTEN logFC are -Infinite (PTEN loss represents a complete depletion of PTEN - complete node inactivation). **C:** Fold change is used by calculate significance using 2 as threshold (log<sub>e</sub>2 = 0.6931472).